Abiraterone for the treatment of metastatic, castrate-resistant prostate cancer following previous cytotoxic chemotherapy TA259
Status In progress
Process STA Review


Key events during the development of the guidance:

Date Update
19 January 2018 In progress, In progress
07 November 2017 - 06 December 2017 Review proposal consultation

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance